$SYRE News

BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132

Spyre Therapeutics Launches New Combination Program SPY772, Comprising Long-Acting Anti-TL1A Antibody SPY072 And Novel Long-Acting Anti-IL-17A/F Antibody In Preclinical Development SPY007

Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115

Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130

Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130

Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate

Wolfe Research Downgrades Spyre Therapeutics to Peer Perform

Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data

Spyre Therapeutics Files Prospectus For Offering Mixed Shelf; Terms Undisclosed

Spyre Therapeutics: A Platform Where The Combination Strategy Is The Real Asset

What's Going On With Spyre Therapeutics Stock On Wednesday?

Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $135

Spyre Therapeutics Announces 12-Week Induction Data From Part A Of Phase 2 SKYLINE Study Of SPY002 To Treat Active Ulcerative Colitis Meets Primary Endpoint; SPY002 Well Tolerated With Consistent Safety Profile

Spyre Therapeutics, Inc. (SYRE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Deutsche Bank Maintains Buy on Spyre Therapeutics, Raises Price Target to $115

Spyre Therapeutics Completes Enrollment For All Sub-Studies In SKYWAY Basket Trial Of SPY072 In Rheumatic Diseases

Why Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License Terms

Spyre Therapeutics Expands SPY003 Rights Beyond IBD Through Amended Paragon License Agreement

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares